长春瑞滨治疗吡柔比星耐药肺癌的疗效观察

The therapeutic effcct of Navelbine chemotherapy in Pirarubicin-resistant lung cancer

目的研究长春瑞滨(NVB)联合顺铂(DDP)方案(NP方案)治疗吡柔比星(THP)方案耐药的晚期非小细胞肺癌(NSCLC)复发、转移的近期疗效和毒副反应。方法用NP方案对曾用THP方案治疗大于2周期后进展或复发、转移的晚期非小细胞肺癌41例进行治疗,21d为1周期,完成2周期后评价疗效。结果部分缓解(PR)17例,稳定(SD)15例,进展(PD)9例,总有效率41.5%。WHO标准Ⅲ、Ⅳ度白细胞下降占87.9%,主要为血液毒性。结论长春瑞滨联合顺铂治疗吡柔比星耐药的晚期非小细胞肺癌仍是可供选择的有效方案,疗效确切,毒副反应可耐受。

Objective To evaluate the efficacy and toxicity of Navelbine （NVB）combined with Cisplatin（DDP） so -called NP regimen in the treatment of Pirarubiein （THP） - resistant advanced stage non - small - cell lung cancer（NSCLC）. Methods 41 patients with advanced NSCLC, that had treated with THP for more than 2 cycles, were treated with Navelbine combined with Cisplatin for 2 cycles every 21 days,and their clinical response and the toxicity were assessed after 2 cycles of chemotherapy. Results Partial response was oboerved in 17 ,and the overall response rate was 41.5%. The dose limiting toxicity was neutropenia that was observed in 87.9%. Conclusions The regimen of NVB plus DDP was effective for treating advanced stage NSCLC which was resistant to THP,and its side effects could be tolerated,